二肽基肽酶Ⅳ／CD26在慢性阻塞性肺疾病中的研究进展  

Research progress of the dipeptidyl peptidase Ⅳ/CD26 in chronic obstructive pulmonary disease

作　　者：杨勇[1] 常晓悦[2] 彭丽娜[3] 

机构地区：[1]内蒙古医科大学研究生学院,呼和浩特010110 [2]包头市中心医院呼吸科,014040 [3]内蒙古科技大学包头医学院,包头014040

出　　处：《国际呼吸杂志》2013年第15期1178-1181,共4页International Journal of Respiration

摘　　要：慢性阻塞性肺疾病（COPD）是一种以持续存在气流受限为特征，以气道、肺实质及肺血管的慢性炎症为核心的多因素构成的慢性疾病。二肽基肽酶Ⅳ分布于人体多种组织中，参与了许多不同的生理过程，其中血清中可溶性二肽基肽酶Ⅳ（sDPPⅣ）水平改变可能与多种疾病有关。有研究显示，COPD患者血清sDPPⅣ浓度明显降低，且与年龄、吸烟因素无关，可能对COPD有早期血清学辅助诊断意义。Chronic obstructive pulmonary disease（COPD） is a type of chronic disease characterized by progressive airflow limitation,which is composed by core factors, such as airway,lung parenchyma and pulmonary vascular chronic inflammation. Dipeptidyl peptidase Ⅳ is distributed in various body tissues, participating in various physiological procedures. Charges in the level of serum soluble dipeptidyl peptidase Ⅳ （sDPPⅣ） may be related to many diseases. It has been shown that sDPPⅣ concentration in serum is not related with age or smoking, thus it may be of significance in early serological diagnosis of COPD.

关 键 词：二肽基肽酶Ⅳ 慢性阻塞性肺疾病 炎症 

分 类 号：R563.9[医药卫生—呼吸系统]